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Abstract Much biomedical research is observational. The reporting of such research is often inadequate, which hampers the assessment 
of its strengths and weaknesses and of a study’s generalizability. The Strengthening the Reporting of Observational Studies in Epidemiology 
(STROBE) Initiative developed recommendations on what should be included in an accurate and complete report of an observational 
study. We defined the scope of the recommendations to cover three main study designs: cohort, case-control and cross-sectional studies. 
We convened a two-day workshop, in September 2004, with methodologists, researchers and journal editors to draft a checklist of items. 
This list was subsequently revised during several meetings of the coordinating group and in e-mail discussions with the larger group 
of STROBE contributors, taking into account empirical evidence and methodological considerations. The workshop and the subsequent 
iterative process of consultation and revision resulted in a checklist of 22 items (the STROBE Statement) that relate to the title, abstract, 
introduction, methods, results and discussion sections of articles. Eighteen items are common to all three study designs and four are 
specific for cohort, case-control, or cross-sectional studies. A detailed Explanation and Elaboration document is published separately 
and is freely available on the web sites of PLoS Medicine, Annals of Internal Medicine and Epidemiology. We hope that the STROBE 
Statement will contribute to improving the quality of reporting of observational studies.
Bulletin of the World Health Organization 2007;85:867–872.
Une traduction en français de ce résumé figure à la fin de l’article. Al final del artículo se facilita una traducción al español.
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Introduction
Many questions in medical research are in-
vestigated in observational studies.1 Much 
of the research into the cause of diseases 
relies on cohort, case-control or cross-
sectional studies. Observational studies 
also have a role in research into the benefits 
and harms of medical interventions.2 Ran-
domized trials cannot answer all important 
questions about a given intervention. For 
example, observational studies are more 
suitable to detect rare or late adverse ef-
fects of treatments, and are more likely to 
provide an indication of what is achieved 
in daily medical practice.3
Research should be reported transpar-
ently so that readers can follow what was 
planned, what was done, what was found, 
and what conclusions were drawn. The 
credibility of research depends on a critical 
assessment by others of the strengths and 
weaknesses in study design, conduct and 
analysis. Transparent reporting is also 
needed to judge whether and how results 
can be included in systematic reviews.4,5 
However, in published observational 
research important information is often 
missing or unclear. An analysis of epide-
miological studies published in general 
medical and specialist journals found that 
the rationale behind the choice of potential 
confounding variables was often not report-
ed.6 Only few reports of case-control studies 
in psychiatry explained the methods used 
to identify cases and controls.7 In a survey 
of longitudinal studies in stroke research, 
17 of 49 articles (35%) did not specify the 
eligibility criteria.8 Others have argued that 
without sufficient clarity of reporting, the 
benefits of research might be achieved more 
slowly,9 and that there is a need for guidance 
in reporting observational studies.10,11
Recommendations on the report-
ing of research can improve reporting 
quality. The Consolidated Standards of 
Reporting Trials (CONSORT) Statement 
was developed in 1996 and revised five 
years later.12 Many medical journals sup-
ported this initiative,13 which has helped 
to improve the quality of reports of 
randomized trials.14,15 Similar initiatives 
have followed for other research areas – 
e.g. for the reporting of meta-analyses 
868 Bulletin of the World Health Organization | November 2007, 85 (11)
Policy and practice
STROBE guidelines for reporting observational studies Erik von Elm et al.
of randomized trials16 or diagnostic 
studies.17 We established a network of 
methodologists, researchers and journal 
editors to develop recommendations for 
the reporting of observational research: 
the Strengthening the Reporting of 
Observational Studies in Epidemiology 
(STROBE) Statement.
Aims and use of the STROBE 
Statement
The STROBE Statement is a checklist of 
items that should be addressed in articles 
reporting on the three main study designs 
of analytical epidemiology: cohort, case-
control and cross-sectional studies. The 
intention is solely to provide guidance 
on how to report observational research 
well: these recommendations are not 
prescriptions for designing or conducting 
studies. Also, while clarity of reporting is a 
prerequisite to evaluation, the checklist is 
not an instrument to evaluate the quality 
of observational research.
Here we present the STROBE State-
ment and explain how it was developed. 
In a detailed companion paper, the 
Explanation and Elaboration article,18–20 
we justify the inclusion of the different 
checklist items, and give methodological 
background and published examples of 
what we consider transparent report-
ing. We strongly recommend using the 
STROBE checklist in conjunction with 
the explanatory article, which is available 
freely on the web sites of PLoS Medicine 
(www.plosmedicine.org), Annals of 
Internal Medicine (www.annals.org) and 
Epidemiology (www.epidem.com).
Development of the STROBE 
Statement
We established the STROBE Initiative 
in 2004, obtained funding for a work-
shop and set up a web site (www.strobe-
statement.org). We searched textbooks, 
bibliographic databases, reference lists 
and personal files for relevant material, 
including previous recommendations, 
empirical studies of reporting and arti-
cles describing relevant methodological 
research. Because observational research 
makes use of many different study de-
signs, we felt that the scope of STROBE 
had to be clearly defined early on. We 
decided to focus on the three study 
designs that are used most widely in ana-
lytical observational research: cohort, 
case-control and cross-sectional studies.
We organized a two-day workshop 
in Bristol, the United Kingdom, in Sep-
tember 2004. Twenty-three individu-
als attended this meeting, including 
editorial staff from Annals of Internal 
Medicine, BMJ, Bulletin of the World 
Health Organization, International Jour-
nal of Epidemiology, JAMA, Preventive 
Medicine and The Lancet as well as epi-
demiologists, methodologists, statisti-
cians and practitioners from Europe and 
North America. Written contributions 
were sought from 10 other individuals 
who declared an interest in contribut-
ing to STROBE, but could not attend. 
Three working groups identified items 
deemed to be important to include in 
checklists for each type of study. A pro-
visional list of items prepared in advance 
(available from our web site) was used 
to facilitate discussions. The three draft 
checklists were then discussed by all 
participants and, where possible, items 
were revised to make them applicable to 
all three study designs. In a final plenary 
session, the group decided on the strat-
egy for finalizing and disseminating the 
STROBE Statement.
After the workshop we drafted a 
combined checklist including all three 
designs and made it available on our 
web site. We invited participants and 
additional scientists and editors to 
comment on this draft checklist. We 
subsequently published three revisions 
on the web site, and two summaries of 
comments received and changes made. 
During this process the coordinating 
group (i.e. the authors of the present 
paper) met on eight occasions for one 
or two days, and held several telephone 
conferences to revise the checklist and 
to prepare the present paper and the 
Explanation and Elaboration paper.18–20 
The coordinating group invited three 
additional co-authors with method-
ological and editorial expertise to help 
write the Explanation and Elaboration 
paper, and sought feedback from more 
than 30 people, who are listed at the end 
of this paper. We allowed several weeks 
for comments on subsequent drafts of 
the paper and reminded collaborators 
about deadlines by e-mail.
STROBE components
The STROBE Statement is a checklist of 
22 items that we consider essential for 
good reporting of observational studies 
(see Table 1). These items relate to the 
article’s title and abstract (item 1), the 
introduction (items 2 and 3), methods 
(items 4–12), results (items 13–17), 
discussion sections (items 18–21) and 
other information (item 22 on fund-
ing). Eighteen items are common to all 
three designs, while four (items 6, 12, 
14 and 15) are design-specific, with dif-
ferent versions for all or part of the item. 
For some items (indicated by footnote a), 
information should be given separately 
for cases and controls in case-control 
studies, or exposed and unexposed 
groups in cohort and cross-sectional 
studies. Although presented here as a 
single checklist, separate checklists are 
available for each of the three study de-
signs on the STROBE web site.
Implications and limitations
The STROBE Statement was developed 
to assist authors when writing up ana-
lytical observational studies, to support 
editors and reviewers when considering 
such articles for publication, and to 
help readers when critically appraising 
published articles. We developed the 
checklist through an open process, tak-
ing into account the experience gained 
with previous initiatives, in particular 
CONSORT. We reviewed the relevant 
empirical evidence as well as method-
ological work, and subjected consecutive 
drafts to an extensive iterative process 
of consultation. The checklist presented 
here is thus based on input from a large 
number of individuals with diverse 
backgrounds and perspectives. The 
comprehensive explanatory article,18–20 
which is intended for use alongside the 
checklist, also benefited greatly from this 
consultation process.
Observational studies serve a wide 
range of purposes, on a continuum from 
the discovery of new findings to the 
confirmation or refutation of previous 
findings.18–20 Some studies are essen-
tially exploratory and raise interesting 
hypotheses. Others pursue clearly de-
fined hypotheses in available data. In yet 
another type of studies, the collection 
of new data is planned carefully on the 
basis of an existing hypothesis. We 
believe the present checklist can be 
useful for all these studies, since the 
readers always need to know what was 
planned (and what was not), what was 
done, what was found, and what the 
results mean. We acknowledge that 
STROBE is currently limited to three 
main observational study designs. We 
would welcome extensions that adapt 
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Table 1. The STROBE Statement: a checklist of items that should be addressed in reports of observational studies
Item Item  
number
Recommendation
Title and abstract 1 (a)  Indicate the study’s design with a commonly used term in the title or the abstract
(b)  Provide in the abstract an informative and balanced summary of what was done and what 
was found
Introduction
Background/rationale 2 Explain the scientific background and rationale for the investigation being reported
Objectives 3 State specific objectives, including any pre-specified hypotheses
Methods
Study design 4 Present key elements of study design early in the paper
Setting 5 Describe the setting, locations and relevant dates, including periods of recruitment, exposure, 
follow-up and data collection
Participants 6 (a)  Cohort study – Give the eligibility criteria, and the sources and methods of selection of 
participants. Describe methods of follow-up
 Case-control study – Give the eligibility criteria, and the sources and methods of case 
ascertainment and control selection. Give the rationale for the choice of cases and controls
 Cross-sectional study – Give the eligibility criteria, and the sources and methods of selection 
of participants
(b)  Cohort study – For matched studies, give matching criteria and number of exposed and 
unexposed
 Case-control study – For matched studies, give matching criteria and the number of controls 
per case
Variables 7 Clearly define all outcomes, exposures, predictors, potential confounders and effect modifiers. 
Give diagnostic criteria, if applicable
Data sources/measurement 8a For each variable of interest, give sources of data and details of methods of assessment 
(measurement). Describe comparability of assessment methods if there is more than one group
Bias 9 Describe any efforts to address potential sources of bias
Study size 10 Explain how the study size was arrived at
Quantitative variables 11 Explain how quantitative variables were handled in the analyses. If applicable, describe which 
groupings were chosen and why
Statistical methods
 
12 (a)  Describe all statistical methods, including those used to control for confounding
(b)  Describe any methods used to examine subgroups and interactions
(c)  Explain how missing data were addressed
(d)  Cohort study – If applicable, explain how loss to follow-up was addressed
 Case-control study – If applicable, explain how matching of cases and controls was addressed 
 Cross-sectional study – If applicable, describe analytical methods taking account of sampling 
strategy
(e)  Describe any sensitivity analyses
Results
Participants 13a (a)  Report the numbers of individuals at each stage of the study – e.g. numbers potentially 
eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-
up and analyzed
(b)  Give reasons for non-participation at each stage
(c)  Consider use of a flow diagram
Descriptive data
 
14a (a)  Give characteristics of study participants (e.g. demographic, clinical, social) and information 
on exposures and potential confounders
(b)  Indicate the number of participants with missing data for each variable of interest
(c)  Cohort study – Summarize follow-up time (e.g. average and total amount)
Outcome data 15a Cohort study – Report numbers of outcome events or summary measures over time
Case-control study – Report numbers in each exposure category, or summary measures of 
exposure
Cross-sectional study – Report numbers of outcome events or summary measures
870 Bulletin of the World Health Organization | November 2007, 85 (11)
Policy and practice
STROBE guidelines for reporting observational studies Erik von Elm et al.
Item Item  
number
Recommendation
Main results 16 (a)  Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their 
precision (e.g. 95% confidence interval). Make clear which confounders were adjusted for 
and why they were included 
(b)  Report category boundaries when continuous variables were categorized 
(c)  If relevant, consider translating estimates of relative risk into absolute risk for a meaningful 
time period
Other analyses 17 Report other analyses done – e.g. analyses of subgroups and interactions, and sensitivity 
analyses 
 Discussion
Key results 18 Summarize key results with reference to study objectives
Limitations 19 Discuss limitations of the study, taking into account sources of potential bias or imprecision. 
Discuss both direction and magnitude of any potential bias
Interpretation 20 Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of 
analyses, results from similar studies, and other relevant evidence 
Generalizability 21 Discuss the generalizability (external validity) of the study results
Other information
Funding 22 Give the source of funding and the role of the funders for the present study and, if applicable, 
for the original study on which the present article is based
a  Give such information separately for cases and controls in case-control studies, and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.
An Explanation and Elaboration article18–20 discusses each checklist item, and gives methodological background and published examples of transparent 
reporting. The STROBE checklist is best used in conjunction with this article (freely available on the web sites of PLoS Medicine, Annals of Internal Medicine and 
Epidemiology ). Separate versions of the checklist for cohort, case-control and cross-sectional studies are available on the STROBE web site.
(Table 1, cont.)
the checklist to other designs – e.g. 
case-crossover studies or ecological stud-
ies – and also to specific topic areas. 
Four extensions are now available for 
the CONSORT Statement.21–24 A first 
extension to STROBE is under way for 
gene–disease association studies: the 
STROBE Extension to Genetic Associa-
tion studies (STREGA) initiative.25 We 
ask those who aim to develop extensions 
of the STROBE Statement to contact 
the coordinating group first to avoid 
duplication of effort.
The STROBE Statement should not 
be interpreted as an attempt to prescribe 
the reporting of observational research 
in a rigid format. The checklist items 
should be addressed in sufficient detail 
and with clarity somewhere in an article, 
but the order and format for presenting 
information depends on author prefer-
ences, journal style and the traditions of 
the research field. For instance, we discuss 
the reporting of results under several 
separate items, while recognizing that au-
thors might address several items within 
a single section of text or in a table. Also, 
item 22, on the source of funding and the 
role of funders, could be addressed in an 
appendix or in the methods section of the 
article. We do not aim at standardizing 
reporting. Authors of randomized clinical 
trials were asked by an editor of a special-
ist medical journal to “CONSORT” 
their manuscripts on submission.26 We 
believe that manuscripts should not be 
“STROBEd”, in the sense of regulat-
ing style or terminology. We encourage 
authors to use narrative elements, includ-
ing the description of illustrative cases, 
to complement the essential informa-
tion about their study, and to make their 
articles an interesting read.27
We emphasize that the STROBE 
Statement was not developed as a tool 
for assessing the quality of published 
observational research. Such instru-
ments have been developed by other 
groups and were the subject of a recent 
systematic review.28 In the Explanation 
and Elaboration paper, we used several 
examples of good reporting from stud-
ies whose results were not confirmed in 
further research – the important feature 
was the good reporting, not whether the 
research was of good quality. However, 
if STROBE is adopted by authors and 
journals, issues such as confounding, bias 
and generalizability could become more 
transparent, which might help temper 
the over-enthusiastic reporting of new 
findings in the scientific community 
and popular media,29 and improve the 
methodology of studies in the long 
term. Better reporting may also help to 
have more informed decisions about 
when new studies are needed and what 
they should address.
We did not undertake a compre-
hensive systematic review for each of the 
checklist items and sub-items, or do our 
own research to fill gaps in the evidence 
base. Further, although no one was 
excluded from the process, the composi-
tion of the group of contributors was 
influenced by existing networks and was 
not representative in terms of geography 
(it was dominated by contributors from 
Europe and North America) and probably 
was not representative in terms of research 
interests and disciplines. We stress that 
STROBE and other recommendations 
on the reporting of research should be 
seen as evolving documents that require 
continual assessment, refinement, and, 
if necessary, change. We welcome sug-
gestions for the further dissemination of 
STROBE – e.g. by re-publication of the 
present article in specialist journals and 
in journals published in other languages. 
Groups or individuals who intend to 
translate the checklist to other languages 
should consult the coordinating group 
beforehand. We will revise the checklist in 
the future, taking into account comments, 
criticism, new evidence and experience 
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from its use. We invite readers to submit 
their comments via the STROBE web 
site (www.strobe-statement.org).  ■
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Résumé
Déclaration de l’Initiative STROBE (Strengthening the Reporting of Observational Studies in 
Epidemiology) : recommandations pour l’élaboration des rapports d’études observationnelles
Les recherches menées dans le domaine biomédical sont pour 
une grande part de nature observationnelle. Les rapports de ces 
études sont souvent inadéquats, ce qui empêche l’évaluation 
des points forts et des défauts de l’étude et sa généralisation. 
L’Initiative STROBE (Strengthening the Reporting of Observational 
Studies in Epidemiology) a élaboré des recommandations sur ce 
que doit être le contenu d’un rapport complet et précis d’étude 
observationnelle. Nous avons défini le champ d’application 
de ces recommandations comme couvrant les trois principaux 
types d’étude, à savoir les études de cohorte, cas-témoins et 
transversales. En septembre 2004, dans le cadre d’un atelier 
de deux jours, nous avons invité des méthodologistes, des 
chercheurs et des éditeurs de revue à élaborer une liste de points 
à considérer. Cette liste a ensuite été révisée dans le cadre de 
plusieurs réunions du groupe coordinateur et de discussions par 
courrier électronique avec le groupe plus large des contributeurs 
à l’Initiative STROBE, en tenant compte de résultats empiriques 
et de considérations méthodologiques. L’atelier et le processus 
itératif ultérieur de consultation et de révision ont débouché sur 
une liste de contrôle en 22 points (la déclaration STROBE) 
concernant le titre, le résumé, l’introduction, la méthodologie 
et les parties Résultats et Discussion des articles. Dix-huit 
points s’appliquent collectivement aux trois types d’étude et 
quatre spécifiquement aux études de cohortes, cas-témoins ou 
transversales. Un document intitulé Explanation and Elaboration est 
publié séparément et accessible gratuitement sur les sites Internet 
PloS Medicine, Annals of Internal Medicine et Epidemiology. Nous 
espérons que la déclaration STROBE contribuera à l’amélioration 
de la qualité des rapports d’étude observationnelle.
Gran parte de la investigación biomédica es de tipo observacional, 
pero la información difundida sobre esas investigaciones es a 
menudo insuficiente, lo que dificulta la evaluación de sus puntos 
fuertes y débiles y de su generalizabilidad de las conclusiones. 
En el marco de la iniciativa de Fortalecimiento de la Notificación 
de los Estudios Observacionales en Epidemiología (STROBE), se 
formularon recomendaciones sobre lo que debería contener una 
notificación precisa de un estudio observacional. Decidimos limitar 
el alcance de las recomendaciones a tres grandes modalidades 
de estudio: estudios de cohortes, estudios de casos y controles, 
y estudios transversales. En septiembre de 2004 organizamos un 
taller de dos días con metodólogos, investigadores y editores de 
revistas para elaborar una lista de verificación de distintos puntos. 
Esta lista fue revisada posteriormente en varias reuniones del 
grupo de coordinación y en discusiones mantenidas por e-mail 
Resumen
Declaración de la Iniciativa STOBE (Strengthening the Reporting of Observational Studies in 
Epidemiology): directrices para informar sobre los estudios observacionales
con los principales participantes en STROBE, teniendo en cuenta 
la evidencia empírica y diversas consideraciones metodológicas. 
El taller y el posterior proceso iterativo de consulta y revisión 
desembocaron en una lista de verificación de 22 puntos (la 
declaración STROBE) que guardan relación con el título, el 
resumen, la introducción y las secciones de métodos, resultados 
y discusión de los artículos. Dieciocho puntos son comunes a las 
tres modalidades de estudio, y cuatro se refieren específicamente 
a los estudios de cohortes, de casos y controles o transversales. 
Se ha publicado separadamente un documento de Explicación y 
elaboración al que puede accederse libremente en los sitios web 
de PLoS Medicine, Annals of Internal Medicine y Epidemiology. 
Esperamos que la declaración STROBE contribuya a mejorar la 
calidad de la notificación de los estudios observacionales.
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صخلم
 ريراقت دادعإ لوح ةيداشرإ لئلاد :STROBE بوترس نايب :تايئابولا لاجم في ةبقارلما لىع ةئماقلا تاساردلا ريراقت دادعإ ةيلمع زيزعت
ةبقارلما لىع ةئماقلا تاساردلا
 بعصي ام ًابلاغو ،ةبقارلما لىع ةيجولويبلا ةيبطلا ثاحبلأا نم ديدعلا موقي
 نطاومو ةوقلا عضاوم ميـيقت قوعي مام ،تاساردلا كلت نع ريراقتلا دادعإ
 نع تأشن  دقلو  .اهيف  ميمعتلا  ةيناكمإ  كلذكو ،ثاحبلأا  هذه في فعضلا
 لاجم في ةبقارلما  لىع ةئماقلا  تاساردلا  ريراقت  دادعإ  ةيلمع زيزعت  ةردابم
 ىدحإ نع لماكو قيقد ريرقت همضي نأ يغبني ام لوح تايصوت تايئابولا
 تايصوتلا هذه قاطنل ًافيرعت نوثحابلا مدقو .ةبقارلما لىع ةئماقلا تاساردلا
 ،ةيبارتلأا تاساردلا :يه ةيثحبلا تاساردلا نم ةيسيئر لاكشأ ةثلاث يطغي
 ةقلح  نوثحابلا  دقعو  .ةيضرعلا  تاساردلاو  ،دهاوشلاو  تلااحلا  تاساردو
 ،نوثحابو ،نويجاهنم اهضرح ،2004  برمتبس/لوليأ  في ناموي  اهتدم ةيلمع
 نأ يغبني يتلا دونبلل ةيدقفت ةئماقل ةد َّوسم عضول ،ةيبط تلاجم وررحمو
 ةدع في حيقنتلل  ًاقحلا ةئماقلا  هذه تعضخو .ريراقتلا  كلت  لثم  اهنمضتت
 لئاسرلا  لدابت  للاخ  نم  كلذكو  ،ةيقيسنتلا  ةعومجلما  اهتدقع  تاعماتجا
 ،STROBE  بوترس نايب  في ينكراشلما  نم بركلأا ةعومجلما ينب ةينوتركللإا
 تض َّختم دقو .نابسحلا في ةيجاهنلما تارابتعلااو ةيبيرجتلا تانِّيبلا ذخأ عم
 ةئماق  نع  ،ةرركتم  حيقنتو  رواشت  تايلمع  نم  اهلات  امو  ةيلمعلا  ةقلحلا
 ناونعب ةقلاع تاذ يهو )STROBE بوترس نايب(  ًادنب 22 مضت ةيدقفت
 .هتلااقبم  ةصاخلا  ةشقانلما  ماسقأو  ثحبلا  جئاتنو  قرطو  ةمدقمو  ةصلاخو
 تاساردلا  لاكشأ  عيمج  ينب  ًاكترشم  ًادنب  شرع ةيناثم  لىع ةئماقلا  لمتشتو
 تاساردلاب ةصاخ ةيعون ًادونب ةيقابلا ةعبرلأا دونبلا دعت مانيب ،ةثلاثلا ةيثحبلا
 لمشت ةلصفنم ةقيثو كانهو .ةيضرعلا  وأ  ،دهاوشلاو تلااحلا  وأ  ،ةيبارتلأا
 يهو ،تنترنلإا  ةكبش لىع ةروشنم ،لاجلما  اذه في ينعسوم ًلايصفتو  ًاحشر
 Annals of Internal Medicine PLoS Medicine يعقوم لىع ًاناجم ةحاتم
 في STROBE بوترس نايب مهسُي نأ في نوثحابلا لمأيو .Epidemiologyو
.ةبقارلما لىع ةئماقلا تاساردلا نع ة َّدعلما ريراقتلا ةيعون ينسحت
